Inovio Pharmaceuticals, Inc. (INO) - What Are Investment Firms Thinking About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Five of eight analysts rate Inovio Pharmaceuticals a buy, two recommend holding, and one rates it a sell. The average 12-month price target is $3.17.
• The stock remains under pressure: INO opened at $0.87, compared with a 52-week range of $0.56 to $2.72, and trades below both its 50-day and 200-day moving averages.
• Institutional ownership is 26.79%: Several hedge funds and investment firms increased their positions, while Inovio reported a quarterly loss of $0.07 per share—better than the expected $0.22 loss.

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have received an average rating of "Moderate Buy" from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $3.17.

INO has been the subject of several analyst reports. Weiss Ratings cut Inovio Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, August 13th. Wall Street Zen upgraded Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Piper Sandler reaffirmed an "overweight" rating and set a $4.00 target price on shares of Inovio Pharmaceuticals in a report on Monday, August 3rd. Jefferies Financial Group upgraded Inovio Pharmaceuticals from a "hold" rating to a "positive" rating and lifted their price target for the company from $1.80 to $3.00 in a research report on Thursday, August 13th. Finally, Zacks Research cut Inovio Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 12th.

Inovio Pharmaceuticals Price Performance

NASDAQ INO opened at $0.87 on Tuesday. Inovio Pharmaceuticals has a 1 year low of $0.56 and a 1 year high of $2.72. The company has a market capitalization of $89.94 million, a PE ratio of -0.96 and a beta of 1.61. The company has a fifty day moving average of $1.17 and a 200 day moving average of $1.28.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. Research analysts expect that Inovio Pharmaceuticals will post -0.72 earnings per share for the current year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Prime Capital Investment Advisors LLC boosted its holdings in Inovio Pharmaceuticals by 312.4% during the third quarter. Prime Capital Investment Advisors LLC now owns 70,636 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 53,510 shares in the last quarter. LexAurum Advisors LLC acquired a new stake in Inovio Pharmaceuticals during the third quarter valued at $118,000. Green Alpha Advisors LLC increased its holdings in Inovio Pharmaceuticals by 68.8% in the third quarter. Green Alpha Advisors LLC now owns 114,857 shares of the biopharmaceutical company's stock valued at $140,000 after buying an additional 46,802 shares in the last quarter. Engineers Gate Manager LP purchased a new position in Inovio Pharmaceuticals in the second quarter valued at $37,000. Finally, Squarepoint Ops LLC increased its holdings in Inovio Pharmaceuticals by 46.5% in the second quarter. Squarepoint Ops LLC now owns 36,391 shares of the biopharmaceutical company's stock valued at $40,000 after buying an additional 11,554 shares in the last quarter. Institutional investors and hedge funds own 26.79% of the company's stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company's platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells.

Inovio's product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.